These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 19670296)

  • 21. Mechanism-based pharmacokinetic-pharmacodynamic modeling of concentration-dependent hysteresis and biphasic electroencephalogram effects of alphaxalone in rats.
    Visser SA; Smulders CJ; Reijers BP; Van der Graaf PH; Peletier LA; Danhof M
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1158-67. PubMed ID: 12183676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemiluminescence determination of gemifloxacin based on diperiodatoargentate (III)-sulphuric acid reaction in a micellar medium.
    Zhao F; Zhao WH; Xiong W
    Luminescence; 2013; 28(2):108-13. PubMed ID: 22362634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in mice.
    Bast DJ; Dresser L; Duncan CL; Walker SE; Mandell LA; Low DE; de Azavedo JC
    J Chemother; 2006 Dec; 18(6):634-40. PubMed ID: 17267342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteers.
    Allen A; Vousden M; Porter A; Lewis A
    Chemotherapy; 1999; 45(6):504-11. PubMed ID: 10567782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic-pharmacodynamic modeling of electroencephalogram effect of imipenem in rats with acute renal failure.
    Dupuis A; Limosin A; Paquereau J; Mimoz O; Couet W; Bouquet S
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3607-9. PubMed ID: 11709350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureus.
    Leonard SN; Kaatz GW; Rucker LR; Rybak MJ
    J Antimicrob Chemother; 2008 Dec; 62(6):1305-10. PubMed ID: 18801920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal antibiotic dosing. The pharmacokinetic-pharmacodynamic interface.
    Reed MD
    Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):17-24. PubMed ID: 19667545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gemifloxacin-associated neurotoxicity presenting as encephalopathy.
    Barrett MJ; Login IS
    Ann Pharmacother; 2009 Apr; 43(4):782-4. PubMed ID: 19276313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats.
    Della Paschoa OE; Mandema JW; Voskuyl RA; Danhof M
    J Pharmacol Exp Ther; 1998 Feb; 284(2):460-6. PubMed ID: 9454785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of effect of gemifloxacin on the steady-state pharmacokinetics of theophylline in healthy volunteers.
    Davy M; Allen A; Bird N; Rost KL; Fuder H
    Chemotherapy; 1999; 45(6):478-84. PubMed ID: 10567778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context.
    Ball P; Mandell L; Patou G; Dankner W; Tillotson G
    Int J Antimicrob Agents; 2004 May; 23(5):421-9. PubMed ID: 15120718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gemifloxacin.
    Lowe MN; Lamb HM
    Drugs; 2000 May; 59(5):1137-47; discussion 1148. PubMed ID: 10852645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic-pharmacodynamic characterization of the cardiovascular, hypnotic, EEG and ventilatory responses to dexmedetomidine in the rat.
    Bol CJJG ; Danhof M; Stanski DR; Mandema JW
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1051-8. PubMed ID: 9399976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.
    Haritova AM; Rusenova NV; Parvanov PR; Lashev LD; Fink-Gremmels J
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3779-85. PubMed ID: 16940071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.
    MacGowan AP; Rogers CA; Holt HA; Wootton M; Bowker KE
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2916-21. PubMed ID: 11557490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-dependent EEG effects of zolpidem provide evidence for GABA(A) receptor subtype selectivity in vivo.
    Visser SA; Wolters FL; van der Graaf PH; Peletier LA; Danhof M
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1251-7. PubMed ID: 12604703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New concept and a theoretical consideration of the mechanism-based pharmacokinetics/ pharmacodynamics (PK/PD) modeling for antimicrobial agents.
    Sato N; Suzuki H; Hayashi H; Shibasaki S; Sugano T; Maebashi K; Kurosawa T; Shiomi M; Ogata H
    Jpn J Antibiot; 2008 Oct; 61(5):314-38. PubMed ID: 19260351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for erythropenia in rats.
    Kobuchi S; Ito Y; Hayakawa T; Nishimura A; Shibata N; Takada K; Sakaeda T
    J Pharmacol Toxicol Methods; 2014; 70(2):134-44. PubMed ID: 25072509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations.
    Visser SA; Wolters FL; Gubbens-Stibbe JM; Tukker E; Van Der Graaf PH; Peletier LA; Danhof M
    J Pharmacol Exp Ther; 2003 Jan; 304(1):88-101. PubMed ID: 12490579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers.
    Davy M; Bird N; Rost KL; Fuder H
    Chemotherapy; 1999; 45(6):491-5. PubMed ID: 10567780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.